2013 Clinical Trials Patients Programs 
Cannabis Law Report
MAY 19, 2022
Andrew Bui-Nguyen, of the Mindspace by Numinus clinic, said in a recent interview. Bui-Nguyen said his clinic received Health Canada’s approval on May 5 to care for a patient who had undergone several unsuccessful treatments for depression. In April, a clinic called Roots To Thrive, in Nanaimo, B.C.,
Cannabis Law Report
FEBRUARY 24, 2022
Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. 01.015 of the FDR before providing the new drug to a patient. Timeline of Medicinal Legalization in Canada. Pursuant to subsection C.08.010(1)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 9, 2021
The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.
Cannabis Law Report
MAY 29, 2022
FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1. DEA and the Controlled Substances Act. (Aug.
Cannabis Law Report
JANUARY 20, 2022
ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Founded in 2013, Eleusis is dedicated to transforming psychedelics into medicines. Silver Spike Acquisition Corp. II is a $287.5
Cannabis Law Report
JULY 25, 2022
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Clinically, Eli is interested in the deep connections between trauma and addiction and works within a neuro-psychoanalytic framework.
The Cannigma
JUNE 15, 2021
Some healthcare professionals are already encouraged by what is known, much of it anecdotal accounts from patients in their practices. The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. A multi-target panacea?
Expert insights. Personalized for you.
52 
Let's personalize your content